HealthRX Tirzepatide Review: Cost, Oral Tablet & Honest Verdict (2026)

HealthRX is a LegitScript-certified (#50087439), physician-supervised telehealth for medical weight loss that is unusual in offering a rare oral GLP tablet alongside the standard injectable, filled by a licensed U.S. 503A pharmacy. This review covers what HealthRX is, what it dispenses, the compounded-versus-brand distinction, its pricing, and the catches. We disclose an affiliate relationship with HealthRX; it never changes our scoring, and every fact here comes from what the company states about its own program.

What HealthRX is

HealthRX is a physician-supervised telehealth for medical weight loss that is LegitScript-certified (#50087439) — a genuine third-party trust signal most compounded startups lack. A U.S. board-certified physician reviews an online intake and, where appropriate, compounded tirzepatide (and semaglutide) is filled by a licensed U.S. 503A pharmacy with transparent monthly pricing and no insurance required. HealthRX is unusual in offering an oral GLP tablet in addition to the standard injectable.

The compounded-vs-brand question

Two very different products share the name tirzepatide:

• •Brand tirzepatide is Eli Lilly's FDA-approved Zepbound (weight management, obstructive sleep apnea) and Mounjaro (type 2 diabetes) — the exact molecule and dose studied in the pivotal trials.
• •Compounded tirzepatide is pharmacy-made, not FDA-approved, and was not the product tested in those trials.

HealthRX's main tirzepatide offerings are compounded (through a 503A pharmacy), with a brand pass-through option quoted separately at a much higher price. That distinction matters more in 2026: the FDA declared the tirzepatide shortage resolved in October 2024, and the enforcement discretion that permitted routine large-scale compounding ended in early 2025 (around February 18, 2025 for 503A pharmacies, March 19, 2025 for 503B outsourcing facilities) — the full timeline is in our guide to whether compounded tirzepatide is still legal in 2026. The oral GLP tablet in particular lacks the injectable's robust absorption and efficacy evidence.

What HealthRX costs in 2026

Company-stated tiers run about $189/month for the compounded GLP injectable, ~$239/month for the oral tablet, and ~$349/month for a GLP+GIP option, with a brand pass-through option quoted around $1,299. Pricing is described as transparent with no insurance required. The honest caveat is that several of these tiers are stated by the company rather than confirmed on a live public price page during our review, and the number of states served is not published — so verify the price and availability in your state directly.

For context, LillyDirect sells brand Zepbound self-pay vials at roughly $299–$449/month depending on dose (prices effective February 23, 2026; 28-day supply) — well below HealthRX's ~$1,299 brand pass-through, so if you want the brand drug, LillyDirect is likely the cheaper route. For the full cash-price picture, see our Zepbound cost and savings guide.

How the care model holds up

HealthRX's strengths are its LegitScript certification (#50087439) — a real trust signal — physician supervision with a licensed U.S. 503A compounding pharmacy, a rare oral GLP tablet alongside injectable, and transparent monthly pricing with no insurance required. The trade-offs: the main tirzepatide is compounded and not FDA-approved; several tiers are company-stated and could not be independently verified on a live page; the brand tier is an expensive pass-through (~$1,299) — far above LillyDirect; and the number of states served is not published. Tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Separate the provider from the medication, and the brand molecule from a compounded copy. Brand tirzepatide's efficacy is trial-grade: in the 72-week SURMOUNT-1 trial, adults without diabetes lost on average roughly 15% to 21% of body weight across the 5–15 mg doses, versus about 3% on placebo¹; against semaglutide in SURMOUNT-5, tirzepatide produced significantly greater weight loss — about 20% versus 14%². Those results were established with the brand injectable molecule; compounded versions — and especially the oral tablet — were never tested in those trials, so the trial efficacy cannot be assumed to transfer. The full picture is in our tirzepatide evidence guide and our look at oral tirzepatide.

The honest verdict

HealthRX is a reasonable pick if you value a LegitScript-certified, physician-supervised program with a 503A pharmacy and want a rare oral GLP tablet option — and you are comfortable with a compounded, non-FDA-approved product. The LegitScript certification is a genuine plus. The reservations are that several tiers are company-stated and unverified, the brand pass-through (~$1,299) is far above LillyDirect, and the states served are not published. If you want the brand drug, LillyDirect is likely cheaper; if you want a flat, verifiable compounded price with included support, weigh CoreAge Rx. See our best tirzepatide providers ranking and best place to get Zepbound online roundup.